Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 695

1.

Human papillomavirus vaccines.

Satyaprakash A, Creed R, Ravanfar P, Mendoza N.

Dermatol Ther. 2009 Mar-Apr;22(2):150-7. doi: 10.1111/j.1529-8019.2009.01227.x. Review.

PMID:
19335726
2.

Currently approved prophylactic HPV vaccines.

Harper DM.

Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123. Review.

PMID:
19943762
3.

[Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].

Lazcano-Ponce E, Salmerón-Castro J, García-Carrancá A, Aranda-Flores C, Madrid-Marina V, Gómez-Altamirano CM, Martínez-Montañez OG.

Salud Publica Mex. 2009 Jul-Aug;51(4):336-41. Spanish. No abstract available.

4.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

PMID:
17682997
5.

Harnessing the power of prevention: human papillomavirus vaccines.

Mayeaux EJ Jr.

Curr Opin Obstet Gynecol. 2006 Feb;18 Suppl 1:s15-21. Review.

PMID:
16520680
6.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
7.

The epidemiology behind the HPV vaccine discovery.

Koutsky L.

Ann Epidemiol. 2009 Apr;19(4):239-44. doi: 10.1016/j.annepidem.2009.01.023. Review.

PMID:
19344861
8.

Prevention strategies against the human papillomavirus: the effectiveness of vaccination.

Stanley M.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S19-23. Review.

PMID:
17938013
9.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

PMID:
19236277
10.

Human papillomavirus vaccine: widening the scope for cancer prevention.

No JH, Kim MK, Jeon YT, Kim YB, Song YS.

Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. Review.

PMID:
21465574
11.

Human papillomavirus vaccines: an update for gynecologists.

Ault KA.

Clin Obstet Gynecol. 2008 Sep;51(3):527-32. doi: 10.1097/GRF.0b013e31818092df. Review.

PMID:
18677145
12.

Cervical cancers after human papillomavirus vaccination.

Beller U, Abu-Rustum NR.

Obstet Gynecol. 2009 Feb;113(2 Pt 2):550-2. doi: 10.1097/AOG.0b013e318191a54a.

PMID:
19155953
13.

The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).

Ansstasiou-Fotaki P, Deligeoroglou E, Kreatsas G.

Akush Ginekol (Sofiia). 2007;46(3):17-20. Bulgarian, English.

PMID:
18018777
14.

Age considerations when vaccinating against HPV.

Wright TC Jr, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ.

Gynecol Oncol. 2008 May;109(2 Suppl):S40-7. doi: 10.1016/j.ygyno.2008.02.002. Review.

PMID:
18482558
15.

Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.

Garcia FA, Saslow D.

Obstet Gynecol Clin North Am. 2007 Dec;34(4):761-81, ix. Review.

PMID:
18061868
16.

[Human papillomavirus vaccines: a new challenge for pediatricians].

Martinón-Torres F, Bernaola Iturbe E, Giménez Sánchez F, Baca Cots M, De Juan Martín F, Díez Domingo J, Garcés Sánchez M, Gómez Campderá JA, Picazo JJ, Pineda Solas V.

An Pediatr (Barc). 2006 Nov;65(5):461-9. Review. Spanish.

17.

One in four California adolescent girls have had human papillomavirus vaccination.

Grant D, Kravitz-Wirtz N, Breen N, Tiro JA, Tsui J.

Policy Brief UCLA Cent Health Policy Res. 2009 Feb;(PB2009-3):1-6. No abstract available.

18.

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

Dunne EF, Datta SD, E Markowitz L.

Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763. Review.

19.

Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.

Herrero R.

J Infect Dis. 2009 Apr 1;199(7):919-22. doi: 10.1086/597308. No abstract available.

PMID:
19236278
20.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

PMID:
19236279

Supplemental Content

Support Center